Camrelizumab  (Synonyms: 卡瑞利珠单抗; SHR-1210)

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al^[1][2].

IC50: 0.70 nM ( PD-1/PD-L1 interaction)^[1]

在使用结核菌素处理的外周血单核细胞进行的 T 细胞增殖试验中，Camrelizumab 在 EC₅₀ 为 0.11 nM 时诱导 T 细胞增殖。在测量 IFN-gamma 分泌的类似测定中，Camrelizumab 以 0.38 nM 的 EC₅₀ 诱导 IFN-gamma 的产生^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Camrelizumab (3 mg/kg) 与 Apatinib (200 和 100 mg/kg) 联合抑制人 PD-1 转基因小鼠的肿瘤的抑制率分别达到 63.1% 和 87.3%^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1798286-48-2

固体

White to light yellow

卡瑞利珠单抗

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kuimin Mei, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9(3):e002191.  [Content Brief]

  [2]. Jason D Lickliter, et al.A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther  [Content Brief]

  [3]. Caicun Zho, et al.Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021 Mar;9(3):305-314.  [Content Brief]